Blood Product Market is expected to Grow at a CAGR of 5.98% through 2030
Advancements in
medical treatments, surgical procedures, and trauma care is expected to drive
the Global Blood Product Market growth in the forecast period, 2026-2030.
According to
TechSci Research report, “Blood Product Market – Global Industry Size,
Share, Trends, Competition, Forecast & Opportunities, 2020-2030F”,
the Global Blood Product Market stood at USD 44.09 Billion in 2024 and is
expected to reach USD 62.62 Billion by 2030 with a CAGR of 5.98% during the
forecast period.
The global blood
product market is experiencing significant growth, driven by various factors,
including the increasing demand for blood products across medical sectors,
advancements in healthcare infrastructure, and a growing awareness of the
importance of blood donations. Blood products, which include red blood cells,
platelets, fresh frozen plasma, and other blood derivatives like
immunoglobulins and albumin, are critical components in treating a wide range
of conditions, such as trauma, surgical blood loss, cancer, anemia, and chronic
diseases. The growing global population, coupled with the rising prevalence of
conditions requiring blood transfusions, is expected to fuel the demand for
blood products worldwide.
In developed
regions like North America and Europe, healthcare systems are well-established,
and there is a consistent need for blood products due to the high number of
surgeries, trauma incidents, and a rising aging population. Countries in these
regions have made significant strides in the collection, processing, and
distribution of blood products. Blood banks and plasma centers are
strategically located to ensure the continuous supply of blood products to
hospitals. In particular, North America, led by the United States, is the
dominant player in the global blood product market, benefiting from a
well-organized and regulated blood collection and transfusion network. The
American Red Cross, along with other regional organizations, plays a crucial
role in blood collection and storage, ensuring that hospitals have timely
access to necessary blood components. As the demand for blood products
continues to rise in these regions, the market has also witnessed improvements
in blood storage and processing technology, increasing the efficiency of blood
supply chains.
In Europe,
countries with well-developed healthcare systems, such as Germany, France, and
the United Kingdom, have also contributed to the steady growth of the blood
product market. Europe faces challenges related to the aging population and the
rising incidence of non-communicable diseases, including cancer, cardiovascular
disease, and diabetes, all of which increase the need for blood transfusions.
The demand for blood products in Europe is expected to continue to rise as
these health challenges intensify. Many European countries have
well-established networks for plasma collection and blood donation, ensuring
that hospitals and medical centers are adequately stocked. The use of
plasma-derived products like immunoglobulins and albumin has been increasing,
especially in treating autoimmune diseases, immune deficiencies, and other
chronic conditions.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Blood Product Market”
The Global Blood
Product Market is segmented into type, application, regional distribution, and
company.
Based on type, the
fresh frozen plasma (FFP) is the second dominant blood product in the global
blood product market. While red blood cells remain the most commonly used and
in-demand blood product, FFP plays a critical role in medical treatments,
making it an essential component of the global blood product market. Fresh
frozen plasma is a blood product that contains water, electrolytes, hormones,
and proteins, including clotting factors, fibrinogen, and albumin, which are
vital for coagulation and maintaining blood volume. This product is used
primarily in treating bleeding disorders, trauma patients, and those undergoing
surgery.
The increasing
prevalence of coagulation disorders and bleeding conditions has been one of the
primary drivers for the rising demand for FFP. Patients suffering from diseases
such as hemophilia, von Willebrand disease, and liver disease often experience difficulties
with blood clotting, requiring plasma transfusions to help manage their
condition. FFP is also commonly used in cases of acute blood loss, where
patients need to replace lost clotting factors and maintain normal coagulation
functions. The use of FFP in trauma care is critical, especially in emergency
settings, where rapid transfusions of plasma can help stabilize patients by
supporting clotting and preventing excessive blood loss. Fresh frozen plasma is
also increasingly used in surgical procedures, particularly those involving
large blood loss, such as cardiac surgery, trauma surgery, and organ
transplantation. During major surgeries, there is often a substantial loss of
blood, and FFP helps to replace not just the volume of blood lost but also the
vital clotting factors that are necessary to prevent post-surgical bleeding
complications. Neonatal care is another key area where FFP is utilized, as
premature infants or newborns may require plasma transfusions to treat or
prevent clotting disorders.
Based on region,
Europe is the second-dominating region in the global blood product market.
While North America, particularly the United States, remains the leader, Europe
has a strong presence in the global market due to its advanced healthcare
infrastructure, well-established blood collection and transfusion systems, and
a growing demand for blood products driven by an aging population and rising
chronic diseases. European countries like Germany, France, the United Kingdom,
and Italy have some of the most developed healthcare systems globally, with a
robust network of hospitals, blood banks, and plasma centers. These countries
have comprehensive blood donation programs, ensuring a steady supply of blood
products to meet the growing demand. The blood product market in Europe
benefits from highly regulated environments and established guidelines set by
both national and international health organizations. The European Medicines
Agency (EMA) and other regulatory bodies ensure that blood products are safe,
effective, and processed according to stringent quality standards.
One of the key
drivers of the European blood product market is the aging population. As the
median age increases across Europe, the demand for blood products such as red
blood cells, fresh frozen plasma, and platelet concentrates has grown. Elderly
individuals are more likely to experience chronic health conditions such as
cancer, cardiovascular diseases, and anemia, all of which require blood
transfusions. The rise in surgical procedures and medical treatments related to
age-related conditions has also led to higher usage of blood products in
hospitals.
Another
contributing factor is the rising prevalence of chronic diseases. Europe has a
significant number of patients suffering from diseases like cancer, anemia,
liver cirrhosis, and kidney failure, conditions that often require regular
blood transfusions. For instance, cancer patients undergoing chemotherapy often
experience a reduction in blood cell counts and require transfusions of red
blood cells and platelets to maintain proper blood cell levels. Similarly,
patients with liver disease or clotting disorders rely heavily on fresh frozen
plasma to treat their conditions. The growing healthcare needs associated with
these chronic diseases have made blood products a key part of European medical
care. In addition to the aging population and the rise of chronic diseases,
Europe has a well-established blood donation culture. Countries like the United
Kingdom, Germany, and Spain have long been recognized for their robust blood
donation systems, which encourage citizens to donate blood regularly. In fact,
Europe has some of the highest rates of voluntary blood donations in the world,
contributing to the reliable supply of blood products. The growth of plasma
donation centers in countries like Germany and France has made plasma-derived
products such as immunoglobulins and albumin more readily available, further
driving the market in the region.
Major companies
operating in Global Blood Product Market are:
- CSL Limited
- Takeda Pharmaceutical Company
Limited
- Octapharma AG
- Grifols, S.A.
- Kedrion S.p.A
- Hualan Biological Vaccine Inc.
- Mitsubishi Tanabe Pharma Corporation
- Baxter International Inc.
- Versiti, Inc.
- Bio Products Laboratory Ltd.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The future of
the global blood product market is poised for significant growth, driven by an
aging population, increasing prevalence of chronic diseases, and advancements
in medical treatments. As healthcare systems continue to expand, particularly
in emerging markets, demand for blood products such as red blood cells,
plasma-derived therapies, and platelets is expected to rise. Innovations in
blood processing, storage, and distribution technologies will enhance
efficiency, reduce waste, and improve patient outcomes. The growing awareness
of blood donation and the establishment of more plasma collection centers will
help ensure a steady supply. With increasing healthcare investments,
particularly in Asia Pacific and South America, the global blood product market
is set to expand, catering to the evolving needs of the healthcare sector”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Blood Product Market - Global Industry Size, Share,
Trends, Opportunity, and Forecast, Segmented By Type (Red Blood
Cells, Platelets, Fresh Frozen Plasma, White Blood Cells, and Others), By
Application (Blood Station, Hospitals and Others), By
Region and Competition, 2020-2030F”, has evaluated
the future growth potential of Global Blood Product Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Blood Product Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com